Načítá se...
Synergistic anticancer effects of bufalin and sorafenib by regulating apoptosis associated proteins
As one of the most recognized and well-known drugs for hepatocellular carcinoma (HCC), the antitumor effect of sorafenib against HCC remains to be improved. Bufalin has displayed an antitumor effect in HCC; however, whether the enhanced antitumor effect may be generated with their combined treatment...
Uloženo v:
| Vydáno v: | Mol Med Rep |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
D.A. Spandidos
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5983987/ https://ncbi.nlm.nih.gov/pubmed/29693132 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mmr.2018.8927 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|